Tivic Health Systems(US:TIVC)2025-11-14 21:31Financial Performance - Revenue for Q3 2025 totaled $146,000, a 15.9% increase from $126,000 in Q3 2024[6] - Gross loss for Q3 2025 was $145,000, compared to a gross profit of $44,000 in Q3 2024, primarily due to $230,000 in inventory reserves[6] - Operating expenses increased to $2.3 million in Q3 2025 from $1.5 million in Q3 2024, attributed to the addition of the biopharma business and increased corporate costs[6] - Net loss for Q3 2025 was $2.6 million, compared to a net loss of $1.4 million in Q3 2024[9] - Tivic's gross margin, excluding inventory reserves, was 42% in Q3 2025, compared to 35% in Q3 2024[6] Cash Position - Cash and cash equivalents as of September 30, 2025, were $3.5 million, up from $2.0 million at December 31, 2024[9] Business Development - Tivic completed the transfer of two INDs from Statera Biopharma, enabling clinical trials for Entolimod in neutropenia and cancer-related conditions[6] - The company successfully completed cell line verification, a key step for cGMP manufacturing, necessary for filing a biologics license application with the FDA[6] - The company executed the write-down of ClearUP inventory, resulting in $230,000 of cost of goods sold and $117,000 of other expenses[9] - The company is advancing discussions for deploying Entolimod as a military countermeasure and stockpile drug[6]